At BIO, signs Congress’ tough stance on China is chilling biotech relationships; Psychedelics companies see FDA panel’s vote as a growth opportunity, not a roadblock

Taking stock of the drug industry, from the lab to the medicine chest

June 6, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

ARIANA DREHSLER/AFP via Getty Images STAT+ | At BIO, signs Congress' tough stance on China is chilling biotech relationships At the BIO conference, executives said looming legislation to restrict U.S. biotechs from working with certain Chinese firms was clearly being felt. By Jonathan Wosen and Meghana Keshavan STAT+ | Psychedelics companies see FDA panel's vote as a growth opportunity, not a roadblock "MDMA is approvable, but we can have much more accessible and easier-to-work-with molecules and treatments," one CEO said. By Meghana Keshavan Withdrawal symptoms hit one in six patients stopping antidepressants, review finds A systematic review of 21,000 patients in The Lancet Psychiatry found that 15% experienced symptoms after stopping antidepressants. By Annalisa Merelli Victor Moriyama/Getty Images Opinion: Close a regulatory loophole in the ACA to provide vaccine access for all Americans The ACA requires insurers to cover "routine" vaccines. A loophole forces people with commercial insurance to pay for other important vaccines. By Tom Daschle and Kathleen G. Sebelius

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser